Having trouble accessing articles? Reset your cache.

FDA takes next step in new drug reorganization, including revamping oncology review

FDA announced the establishment of three new offices as part of a wide-ranging reorganization of the Center for Drug Evaluation and Review’s Office of New Drugs.

The new organization is flatter and includes new disease-focused divisions. It is intended to allow FDA to focus more relevant expertise on drug reviews,

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers